Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s ...

March Biosciences, a startup spun out of Baylor College of Medicine's Center for Cell and Gene Therapy, landed a Series A ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack - blocking the ...

This study, being conducted in South Africa, is similar to ImmunityBio’s U.S.-based trial QUILT 3.092, a phase 1 open-label study of CD19 t-haNK as a single agent and in combination with the company’s ...

In 1893, the American Journal of the Medical Sciences reported on 10 patients whose large and hitherto incurable cancers had ...

Both agreed that there have been no trials directly comparing a BsAb therapy vs CAR T cells, so there is no definitive answer, and Landsburg was reluctant to take a hard line on reserving BsAbs until ...

MU Health Care said the new program is the only one of its kind in the region, and may help patients get care without going ...

Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, ...

Strategy for enhancing immune cell infiltration could be combined with other methods to improve cell-based immunotherapies ...

An online survey-based cross-sectional study assessed current practice patterns on the management of post-CAR-T failure in patients with relapsed or refractory multiple myeloma.

Our Lady of the Lake Cancer Institute has launched a new hematologic malignancy cell therapy program, the first of its kind in Baton Rouge.  The leaders of the program—Dr. Hana Safah, medical director ...